These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
85 related articles for article (PubMed ID: 8711587)
1. [Natural history of prostatic adenocarcinoma. Recent advances in prognostic parameters and biological behavior]. Mirone V; Fabrizio F; Longo N; Palmieri A; Cozza PP; Parisi G; Morrone G Minerva Urol Nefrol; 1995 Dec; 47(4):171-5. PubMed ID: 8711587 [TBL] [Abstract][Full Text] [Related]
2. Precursors of prostatic adenocarcinoma: recent findings and new concepts. Eur Urol; 1996; 30(2):131-279. PubMed ID: 8991793 [No Abstract] [Full Text] [Related]
3. Incidental prostate cancer in patients with bladder urothelial carcinoma: comprehensive analysis of 1,476 radical cystoprostatectomy specimens. Bruins HM; Djaladat H; Ahmadi H; Sherrod A; Cai J; Miranda G; Skinner EC; Daneshmand S J Urol; 2013 Nov; 190(5):1704-9. PubMed ID: 23707451 [TBL] [Abstract][Full Text] [Related]
4. [Prostatic involvement by urothelial carcinoma in patients with bladder cancer and their implications in the clinical practice]. Huguet J Actas Urol Esp; 2012 Oct; 36(9):545-53. PubMed ID: 22520044 [TBL] [Abstract][Full Text] [Related]
5. [Metastatic prostate cancer complicated with chronic disseminated intravascular coagulopathy causing acute renal failure, mimicking thrombotic thrombocytopenic purpura and hemolytic uremic syndrome: pathomechanism, differential diagnosis and therapy related to a case]. Deme D; Ragán M; Kalmár K; Kovács L; Varga E; Varga T; Rakonczai E Magy Onkol; 2010 Dec; 54(4):351-7. PubMed ID: 21163766 [TBL] [Abstract][Full Text] [Related]
6. Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development. Cunha GR; Ricke W; Thomson A; Marker PC; Risbridger G; Hayward SW; Wang YZ; Donjacour AA; Kurita T J Steroid Biochem Mol Biol; 2004 Nov; 92(4):221-36. PubMed ID: 15663986 [TBL] [Abstract][Full Text] [Related]
7. [Evolution and prognostic factors of adenocarcinomas of the prostate metastasizing at diagnosis]. Arrizabalaga Moreno M; García González JI; Mora Durvan M; Díez Rodríguez JM; Esteban Artiaga R; Navarro Sebastián J; Castro Pita M; Paniagua Andrés P Actas Urol Esp; 1997 Sep; 21(8):724-36. PubMed ID: 9412221 [TBL] [Abstract][Full Text] [Related]
8. The role of stromal cells in prostate cancer development and progression. Condon MS; Bosland MC In Vivo; 1999; 13(1):61-5. PubMed ID: 10218135 [TBL] [Abstract][Full Text] [Related]
9. Reciprocal mesenchymal-epithelial interaction affecting prostate tumour growth and hormonal responsiveness. Chung LW; Gleave ME; Hsieh JT; Hong SJ; Zhau HE Cancer Surv; 1991; 11():91-121. PubMed ID: 1726790 [TBL] [Abstract][Full Text] [Related]
10. Characterization of reactive stroma in prostate cancer: involvement of growth factors, metalloproteinase matrix, sexual hormones receptors and prostatic stem cells. Silva MM; Matheus WE; Garcia PV; Stopiglia RM; Billis A; Ferreira U; Fávaro WJ Int Braz J Urol; 2015; 41(5):849-58. PubMed ID: 26689510 [TBL] [Abstract][Full Text] [Related]
11. Prostate-derived growth factors for bone cells: implications for bone physiology and pathophysiology: review. Koutsilieris M In Vivo; 1988; 2(6):377-83. PubMed ID: 2979859 [TBL] [Abstract][Full Text] [Related]
12. Gray level entropy matrix is a superior predictor than multiplex ELISA in the detection of reactive stroma and metastatic potential of high-grade prostatic adenocarcinoma. Jia X; Sun Y; Wang B IUBMB Life; 2014 Dec; 66(12):847-53. PubMed ID: 25631296 [TBL] [Abstract][Full Text] [Related]
13. A system for studying epithelial-stromal interactions reveals distinct inductive abilities of stromal cells from benign prostatic hyperplasia and prostate cancer. Barclay WW; Woodruff RD; Hall MC; Cramer SD Endocrinology; 2005 Jan; 146(1):13-8. PubMed ID: 15471963 [TBL] [Abstract][Full Text] [Related]
14. Hormonally responsive versus unresponsive progression of prostatic cancer to antiandrogen therapy as studied with the Dunning R-3327-AT and -G rat adenocarcinomas. Isaacs JT Cancer Res; 1982 Dec; 42(12):5010-4. PubMed ID: 6215981 [TBL] [Abstract][Full Text] [Related]
15. The clinical and biological study of androgen independent prostate cancer (AI PCa). Logothetis CJ; Hoosein NM; Hsieh JT Semin Oncol; 1994 Oct; 21(5):620-9. PubMed ID: 7524155 [No Abstract] [Full Text] [Related]
16. Unopposed c-MYC expression in benign prostatic epithelium causes a cancer phenotype. Williams K; Fernandez S; Stien X; Ishii K; Love HD; Lau YF; Roberts RL; Hayward SW Prostate; 2005 Jun; 63(4):369-84. PubMed ID: 15937962 [TBL] [Abstract][Full Text] [Related]
17. Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Bushman W Urol Clin North Am; 2009 Nov; 36(4):403-15, v. PubMed ID: 19942041 [TBL] [Abstract][Full Text] [Related]
18. High expression of KLK14 in prostatic adenocarcinoma is associated with elevated risk of prostate-specific antigen relapse. Rabien A; Fritzsche F; Jung M; Diamandis EP; Loening SA; Dietel M; Jung K; Stephan C; Kristiansen G Tumour Biol; 2008; 29(1):1-8. PubMed ID: 18497543 [TBL] [Abstract][Full Text] [Related]
19. Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer. Kasper S; Sheppard PC; Yan Y; Pettigrew N; Borowsky AD; Prins GS; Dodd JG; Duckworth ML; Matusik RJ Lab Invest; 1998 Jun; 78(6):i-xv. PubMed ID: 9645768 [TBL] [Abstract][Full Text] [Related]
20. Stromal cell heterogeneity in fibroblast growth factor-mediated stromal-epithelial cell cross-talk in premalignant prostate tumors. Wu X; Jin C; Wang F; Yu C; McKeehan WL Cancer Res; 2003 Aug; 63(16):4936-44. PubMed ID: 12941818 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]